Chk1 KA1 Domain Auto-phosphorylation Stimulates Biological Activity and is Linked to Rapid Proteasomal Degradation

Overview

Journal Sci Rep

Specialty Science

Date 2018 Dec 5

PMID 30510197

Citations 4

Authors

Eun-Yeung Gong

Beatriz Hernandez

Jessica Hernandez Nielsen

Veronique A J Smits

Raimundo Freire

David A Gillespie

Affiliations

Soon will be listed here.

Abstract

The DNA damage-activated protein kinase Chk1 is known to undergo auto-phosphorylation, however the sites and functional significance of this modification remain poorly understood. We have identified two novel Chk1 auto-phosphorylation sites, threonines 378 and 382 (T378/382), located in a highly conserved motif within the C-terminal Kinase Associated 1 (KA1) domain. T378/382 occur within optimal consensus Chk1 phosphorylation motifs and substitution with phospho-mimetic aspartic acid residues results in a constitutively active mutant Chk1 kinase (Chk1-DD) that arrests cell cycle progression in G2 phase of the cell cycle in the absence of DNA damage. Remarkably, the mutant Chk1-DD protein is also subject to very rapid proteasomal degradation, with a half-life approximately one tenth that of wild-type Chk1. Consistent with this, T378/T382 auto-phosphorylation also accelerates the proteasomal degradation of constitutively active Chk1 KA1 domain structural mutants. T378/382 auto-phosphorylation and accelerated degradation of wild-type Chk1 occurs at low levels during unperturbed growth, but surprisingly, is not augmented in response to genotoxic stress. Taken together, these observations demonstrate that Chk1 T378/T382 auto-phosphorylation within the KA1 domain is linked to kinase activation and rapid proteasomal degradation, and suggest a non-canonical mechanism of regulation.

Citing Articles

Spatiotemporal regulation of MELK during mitosis.

Majumdar S, Liu S Front Cell Dev Biol. 2024; 12:1406940.

PMID: 39355119 PMC: 11443572. DOI: 10.3389/fcell.2024.1406940.

Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs.

Hernandez-Suarez B, Gillespie D, Dejnaka E, Kupczyk P, Obminska-Mrukowicz B, Pawlak A Front Vet Sci. 2023; 10:1227683.

PMID: 37655260 PMC: 10467447. DOI: 10.3389/fvets.2023.1227683.

Structural basis for recruitment of the CHK1 DNA damage kinase by the CLASPIN scaffold protein.

Day M, Parry-Morris S, Houghton-Gisby J, Oliver A, Pearl L Structure. 2021; 29(6):531-539.e3.

PMID: 33789090 PMC: 8204404. DOI: 10.1016/j.str.2021.03.007.

CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.

Al-Shari N, Musleh S Mol Divers. 2021; 26(2):903-921.

PMID: 33686514 DOI: 10.1007/s11030-021-10202-w.

References

Emptage R, Lemmon M, Ferguson K . Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase. Biochem J. 2016; 474(3):385-398. PMC: 5317272. DOI: 10.1042/BCJ20160792. View

Gong E, Smits V, Fumagallo F, Piscitello D, Morrice N, Freire R . KA1-targeted regulatory domain mutations activate Chk1 in the absence of DNA damage. Sci Rep. 2015; 5:10856. PMC: 4454167. DOI: 10.1038/srep10856. View

Scorah J, Dong M, Yates 3rd J, Scott M, Gillespie D, McGowan C . A conserved proliferating cell nuclear antigen-interacting protein sequence in Chk1 is required for checkpoint function. J Biol Chem. 2008; 283(25):17250-9. PMC: 2427339. DOI: 10.1074/jbc.M800369200. View

Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson E, Dan C . Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013; 341(6141):84-7. DOI: 10.1126/science.1233606. View

Smith J, Tho L, Xu N, Gillespie D . The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010; 108:73-112. DOI: 10.1016/B978-0-12-380888-2.00003-0. View

Leung-Pineda V, Huh J, Piwnica-Worms H . DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 2009; 69(6):2630-7. PMC: 2776040. DOI: 10.1158/0008-5472.CAN-08-3382. View

Emptage R, Schoenberger M, Ferguson K, Marmorstein R . Intramolecular autoinhibition of checkpoint kinase 1 is mediated by conserved basic motifs of the C-terminal kinase-associated 1 domain. J Biol Chem. 2017; 292(46):19024-19033. PMC: 5704483. DOI: 10.1074/jbc.M117.811265. View

Sanchez-Barrena M, Fujii H, Angulo I, Martinez-Ripoll M, Zhu J, Albert A . The structure of the C-terminal domain of the protein kinase AtSOS2 bound to the calcium sensor AtSOS3. Mol Cell. 2007; 26(3):427-35. PMC: 3137524. DOI: 10.1016/j.molcel.2007.04.013. View

Zhang Y, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A . The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 2009; 35(4):442-53. PMC: 2736145. DOI: 10.1016/j.molcel.2009.06.030. View

10.

Zachos G, Black E, Walker M, Scott M, Vagnarelli P, Earnshaw W . Chk1 is required for spindle checkpoint function. Dev Cell. 2007; 12(2):247-60. PMC: 7115955. DOI: 10.1016/j.devcel.2007.01.003. View

11.

Mackay D, Ullman K . ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission. Mol Biol Cell. 2015; 26(12):2217-26. PMC: 4462940. DOI: 10.1091/mbc.E14-11-1563. View

12.

Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T, Inagaki M . 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J. 2010; 29(16):2802-12. PMC: 2924644. DOI: 10.1038/emboj.2010.157. View

13.

Li P, Goto H, Kasahara K, Matsuyama M, Wang Z, Yatabe Y . P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol Biol Cell. 2012; 23(8):1582-92. PMC: 3327324. DOI: 10.1091/mbc.E11-10-0883. View

14.

Okita N, Minato S, Ohmi E, Tanuma S, Higami Y . DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism. FEBS Lett. 2012; 586(22):3974-9. DOI: 10.1016/j.febslet.2012.09.048. View

15.

Shimada M, Niida H, Zineldeen D, Tagami H, Tanaka M, Saito H . Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell. 2008; 132(2):221-32. DOI: 10.1016/j.cell.2007.12.013. View

16.

Hadders M, Williams R . Kinases charging to the membrane. Cell. 2010; 143(6):865-7. DOI: 10.1016/j.cell.2010.11.044. View

17.

Zhang Y, Otterness D, Chiang G, Xie W, Liu Y, Mercurio F . Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 2005; 19(5):607-18. DOI: 10.1016/j.molcel.2005.07.019. View

18.

Hutchins J, Hughes M, Clarke P . Substrate specificity determinants of the checkpoint protein kinase Chk1. FEBS Lett. 2000; 466(1):91-5. DOI: 10.1016/s0014-5793(99)01763-9. View

19.

Walker M, Black E, Oehler V, Gillespie D, Scott M . Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity. Oncogene. 2009; 28(24):2314-23. PMC: 2857325. DOI: 10.1038/onc.2009.102. View

20.

Smits V, Gillespie D . DNA damage control: regulation and functions of checkpoint kinase 1. FEBS J. 2015; 282(19):3681-92. DOI: 10.1111/febs.13387. View